P4 medicine (predictive, preventive, personalized, participatory) is one of the world's most promising developments for improved, holistic and efficient health care. DigiMed Bayern's goal is to guide Bavaria into this medicine of the future with a lighthouse project.
The lighthouse P4-medicine project DigiMed Bayern was launched at the end of 2018 with over 20 million € funding by the Bavarian State Ministry of Health and Care. DigiMed Bayern combines comprehensive datasets of patients diagnosed with atherosclerotic diseases, such as coronary heart disease and stroke, or with genetic risk factors. This dataset will be further enriched with state-of-the-art multi-dimensional molecular characterization (-omics technologies) of associated sample material. For the integrative analysis of the resulting "Big Data", an ethically and legally compliant, highly secure and sustainable IT infrastructure will be fundamentally designed and implemented. Finally, patients and persons at risk will benefit from advancements in disease risk prediction, targeted prevention, diagnosis and treatment.
Superior goals of DigiMed Bayern
1. Using the example of atherosclerosis, a first analysis of comprehensive data sets in the sense of digital medicine of the future is carried out. All those involved in the health care system in Bavaria should benefit directly: the prediction for coronary heart disease (CHD) and stroke should be made more accurate in the short term and preventive treatment should be improved. In the medium to long term improvements in diagnosis and therapy are pursued. The population-wide identification of familial hypercholesterinemia as an exemplary risk factor for atherosclerosis should be sustainably improved.
2. The technical, legal and social possibilities and limitations of P4 medicine are recorded, promoted and documented by means of concrete implementation. This includes a proactive multi-directional information exchange with all those involved in health, with a focus on systemic development.
3. Resulting insights and structures should be expandable in the health system, in research and in the economy and be transferable to other diseases. In particular, an exemplary and transferable integrated digital infrastructure should be created.
4. Bavaria as a location for P4 medicine should be substantially developed, including international perception and internationally networking.
Q4 2018 to Q4 2023
German Heart Centre Munich
BioM Biotech Cluster Development GmbH
Initially involved Institutions
More information: Description of the work packages of DigiMed Bayern (pdf).
Leon du Toit
Section Leader, Research Services
Services for Sensitive Data, University of Oslo, Center for IT
Prof. Dr. Thomas Berlage
Head of Life Science Informatics
Fraunhofer Institute for Applied Information Technology
Prof. Dr. Martijn A. Spruit
Scientific Advisor CIRO, Professor in Rehabilitation of Chronic Organ Failure, Maastricht University, The Netherlands
Professor in Rehabilitation Sciences and Physiotherapy, Hasselt University, Belgium
Olaf Lodbrok, MBA
Senior Vice President & General Manager, Precision Medicine, Elsevier
Dr. Klaus Heumann
CEO, Biomax Informatics
From Biobanking to Precision Medicine: The Estonian Way
Prof. Dr. Andres Metspalu
The Estonian Genome Center, Institute of Genomics, University of Tartu, Estonia
Catalan open innovation hub on ICT-supported integrated care services for chronic patients
Prof. Dr. Josep Roca
Hospital Clinic de Barcelona. IDIBAPS. University of Barcelona
Systems BioMedicine - trying to merge basic research with health care data
Prof. Dr. Reinhard Schneider
Bioinformatics Core Facility of the Luxembourg Centre for Systems Biomedicine
Systems Medicine - A big data driven disruptive view on current medicine
Prof. Dr. Jan Baumbach
Chair of Experimental Bioinformatics, TU Munich